CD8A and glioblastoma: Although glioblastoma multiforme (GBM), with low populations of M1 macrophages (Figure 5A), might benefit from IL‐12 exposure, the low populations of CD8+ T cells may exhibit a diminished antitumor response with IL‐12 treatment.